This clinical trial is focused on studying a type of prostate cancer known as Metastatic Castration-Resistant Prostate Cancer. This is a form of prostate cancer that continues to grow and spread even when the amount of male hormones in the body is reduced to very low levels. The study is investigating the effects of a new treatment combination involving a medication called Lorigerlimab and another drug named Docetaxel, compared to using Docetaxel alone. Lorigerlimab is a type of protein designed to help the immune system fight cancer by targeting specific proteins on cancer cells.

The purpose of the study is to evaluate how effective the combination of Lorigerlimab and Docetaxel is in treating this type of prostate cancer. Participants in the study will be randomly assigned to receive either the combination of Lorigerlimab and Docetaxel or Docetaxel alone. The study will monitor the participants over a period to see how the cancer responds to the treatment. This includes checking if the cancer stops growing or shrinks, and how long it takes for the cancer to start growing again. The study will also look at the overall health and survival of the participants, as well as any side effects they may experience.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the progress of the cancer. These tests may include imaging scans and blood tests to measure the levels of prostate-specific antigen (PSA), a substance often found in higher amounts in men with prostate cancer. The study aims to provide valuable information on whether the new treatment combination can offer better outcomes for patients with Metastatic Castration-Resistant Prostate Cancer.